gastroenteropancreatic

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…

2 months ago

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

 Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…

2 months ago